Skip to menu Skip to content Skip to footer

2025

Conference Publication

P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor

Moniruzzaman, M., Janjua, T., Begun, J. and Popat, A. (2025). P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0286

P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor

2024

Conference Publication

Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

Bisht, Kavita, An, Yoon-Kyo, Shatunova, Svetlana, Wang, Ran, Barbier, Valerie, Giri, Rabina, Amiss, Anna, Tang, Yifu, Alexander, Kylie, Millard, Susan, Winkler, Ingrid G., Pettit, Allison, Begun, Jakob and Levesque, Jean-Pierre (2024). Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-193349

Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

2024

Conference Publication

The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History

Allegretti, Jessica R., Panés, Julián, Peyrin-Biroulet, Laurent, Sands, Bruce E., Yarandi, Shadi, Huang, Kuan-Hsiang G., Germinaro, Matthew, Zhan, Jia, Zhang, Hongyan, Begun, Jakob, Kierkuś, Jarosław, Kravchenko, Tetiana, Hisamatsu, Tadakazu, Rubin, David T., Bressler, Brian and Dignass, Axel (2024). The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History. 2024 ACG Annual Meeting, Philadelphia, PA United States, 25-30 October 2024. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.14309/01.ajg.0001034328.68326.43

The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History

2024

Conference Publication

A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights program

Seng, Crystal, Su, Wai Kin, Wilson, William, Haifer, Craig, Williams, Astrid-Jane, Forbes, Angela, Lawrance, Ian, Lynch, Kate, Brett, Laurel, Begun, Jakob, Connor, Susan J., Andrews, Jane and Walker, Gareth (2024). A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre study

Gilmore, Robert, Fernandes, Richard, Subhaharan, Deloshaan, Mohsen, Waled, Thin, Lena, Chin, Simone, Con, Danny, De Cruz, Peter, Demase, Kathryn, Sparrow, Miles P., Lucas, Sarah, Garg, Mayur, Bryant, Robert, Segal, Jonathan, Christensen, Britt, Begun, Jakob and An, Yoon-Kyo (2024). Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre study

2024

Conference Publication

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, Emi, Amiss, Anna, Lindsay, Niamh, Fernandes, Richard, Gilmore, Robert, Ding, John Nik, Connor, Susan J., Bryant, Robert, White, Lauren, Mohsen, Waled, Leong, Rupert, Ardalan, Zaid, Croft, Anthony, De Cruz, Peter, Lynch, Kate, An, Yoon-Kyo, Holtmann, Gerald and Begun, Jakob (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

2024

Conference Publication

Age-dependent dysregulation of the UPR in colonic epithelium: Implications for mucosal integrity

Illankoon, Thishan, Wong, Kuan Yau, Sajiir, Haressh, Mueller, Alexandra, Amiss, Anna, Begun, Jakob, Giri, Rabina, Burr, Lucy and Hasnain, Sumaira (2024). Age-dependent dysregulation of the UPR in colonic epithelium: Implications for mucosal integrity. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Age-dependent dysregulation of the UPR in colonic epithelium: Implications for mucosal integrity

2024

Conference Publication

Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series

Swe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series

2024

Conference Publication

The prevalence and impact of obesity in an ANZ cohort of people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

Kaazan, Patricia, Su, Wai Kin, Rayner, Christopher, Walker, Gareth, Wilson, William, Dinoy, Elaine, Wark, Gabrielle, Forbes, Angela, Schultz, Michael, Yap, Jia, Lawrance, Ian, Dutt, Shoma, Lynch, Kate, Brett, Laurel, Begun, Jakob, Andrews, Jane and Connor, Susan J. (2024). The prevalence and impact of obesity in an ANZ cohort of people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

The prevalence and impact of obesity in an ANZ cohort of people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

Mortality in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

Alsulaibi, Owen, Su, Wai Kin, Wilson, William, Sin, Hiu Ching Letisia, Ng, Watson, Walker, Gareth, Forbes, Angela, Lawrance, Ian, Lynch, Kate, Begun, Jakob, Connor, Susan J. and Andrews, Jane (2024). Mortality in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Mortality in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis

Huynh, David, Khaing, Myat, Fernandes, Richard, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2024). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, International Convention Centre Sydney (ICC Sydney), Sydney, NSW, Australia, 9 - 11 September 2022. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.16702

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis

2024

Conference Publication

Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of concept

Giri, Rabina, Amiss, Anna, Riches, Bruce, Carpinelli De Jesus, Matheus and Begun, Jakob (2024). Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of concept. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of concept

2024

Conference Publication

Healthcare utilisation in people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

Su, Wai Kin, Pipicella, Joseph, Wilson, William, Kim, Andrew, Davidson, Chloe, Giles, Edward, Walker, Gareth, Forbes, Angela, Su, Heidi, Lawrance, Ian, Dutt, Shoma, Lynch, Kate, Brett, Laurel, Begun, Jakob, Connor, Susan J. and Andrews, Jane (2024). Healthcare utilisation in people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Healthcare utilisation in people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

The psycho-social impact of fistulising perianal Crohn's disease in Australasia: Crohn's Colitis Cure (CCC) data insights program

Nano, Dominique, Su, Wai Kin, Mcnamara, Jack, Wilson, William, Arzivian, Arteen, Williams, Astrid-Jane, Walker, Gareth, Forbes, Angela, Su, Heidi, Giles, Edward, Lawrance, Ian, Dutt, Shoma, Lynch, Kate, Brett, Laurel, Begun, Jakob, Andrews, Jane and Connor, Susan J. (2024). The psycho-social impact of fistulising perianal Crohn's disease in Australasia: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

The psycho-social impact of fistulising perianal Crohn's disease in Australasia: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, Emi, Amiss, Anna, Ding, Nik S., Bryant, Robert V., Mohsen, Waled, Connor, Susan J., Leong, Rupert, Croft, Anthony, Lynch, Kate D., Sparrow, Miles, De Cruz, Peter, An, Yoon-Kyo, Holtmann, Gerald J. and Begun, Jakob (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Digestive Disease Week (DDW) 2024, Washington, DC, United States, 18-21 May 2024. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(24)00988-0

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

2024

Conference Publication

Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Alshiwanna, Basheer, McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Williams, Astrid-Jane, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Connor, Susan J. and Andrews, Jane M. (2024). Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03074-9

Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

2024

Conference Publication

Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Barnett, Meghan I., McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Williams, Astrid-Jane, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Connor, Susan J. and Andrews, Jane M. (2024). Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03072-5

Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

2024

Conference Publication

A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction

Fernandes, Richard G., Khoo, Emi, Harris, Heidi Jensen, Gilmore, Robert, Khaing, Myat Myat, Begun, Jakob and An, Yoon-Kyo (2024). A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier BV. doi: 10.1016/s0016-5085(24)01652-4

A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction

2024

Conference Publication

Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program

McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Ng, Watson, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Andrews, Jane M. and Connor, Susan J. (2024). Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)02405-3

Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program

2024

Conference Publication

The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's Program

Pipicella, Joseph L., McNamara, Jack, Wilson, William E., Lynch, Kate D., Walker, Gareth J., Begun, Jakob, Lawrance, Ian C., Ghaly, Simon, Radford-Smith, Graham L., Williams, Astrid-Jane, Gearry, Richard, Schultz, Michael, Brett, Laurel, Andrews, Jane M. and Connor, Susan J. (2024). The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03792-2

The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's Program